Invesco Russell 1000 Equal Weight ETF (ARCA: EQAL)

Latest News for Invesco Russell 1000 Equal Weight ETF (ARCA:EQAL)

Invesco Russell 1000 Equal Weight ETF

PowerShares Russell 1000 Equal Weight POrtfolio

Long Ideas

News

Broad U.S. Equity ETFs

Specialty ETFs

New ETFs

Intraday Update

Markets

Trading Ideas

ETFs

EQAL

IDLV

PowerShares S&P 500 Low Volatility Portfolio

SPLV

Come Together: Low Volatility Meets Equal-Weight In These ETFs

Long-Term Investors Should Get To Know This Equal-Weight ETF

Dividends

OUSA

PowerShares Exchange Traded Fund FTSE RAFI US 1000 Portfolio

The Survey Says Advisors Love Smart Beta ETFs

Guidance

SANM

Sanmina Sees Q3 Adj. EPS $1.22-$1.32 vs $1.36 Est., Revenue $1.8B-$1.9B vs $1.97B Est.

At that time,&nbsp;William P. Stengel, II, currently president and COO, will succeed Mr. Donahue as president and CEO of GPC and will serve as a member of the board of directors.

Management

Genuine Parts Says Paul Donahue Will Transition To Executive Chairman, Effective June 3, 2024; Will Stengel Named As President And CEO

Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.39 by 5.13 percent. This is a 6.82 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $53.952 million which missed the analyst consensus estimate of $56.491 million by 4.49 percent. This is a 14.05 percent decrease over sales of $62.773 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

FBRT

Franklin BSP Realty Trust Q1 2024 Adj EPS $0.41 Beats $0.39 Estimate, Sales $53.952M Miss $56.491M Estimate

Amalgamated Financial Corp. ("Amalgamated" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAL#NASDAQ">AMAL</a>) today announced the mechanical completion of three community solar projects in Oregon, with commercial operations expected to commence in April and May of this year. Three additional projects are expected to be completed and commence operations by the end of the third quarter of 2024. &nbsp;
Amalgamated financed the developments by originating a one-of-a-kind $25 million construction term facility to SolRiver Capital ("SolRiver"). Amalgamated and SolRiver agreed to a 7-year term structured with a maximum 18-month interest-only construction period, which converts into a term loan subject to a 20-year amortization for the remainder of the term. The revolving line structure enabled SolRiver to finance the six projects, with construction costs totaling $39 million, without ever holding more than $25 million in outstanding debt on the project.
The completion dates and active production of the six solar projects were staggered. During the construction period draws on the facility represented 85% of the project cost. Upon completion, each project will be sold to a tax equity partnership under a membership interest purchase agreement. The new entity is an institutional-grade tax equity partnership. Proceeds from the sale will be used to pay down the construction loan, at which point the loan converts to a term loan with a long amortization schedule.
Priscilla Sims Brown, President and Chief Executive Officer, commented, "Amalgamated congratulates our client SolRiver on delivering three community solar developments. We are thrilled to finance this project with an innovative financial solution, and extremely proud to play an active role in advancing the Oregon Community Solar Program. Our collaboration with SolRiver Capital further demonstrates how Amalgamated is uniquely positioned to underwrite inventive sustainable lending solutions, displaying our ongoing commitment to help combat climate change while executing on our socially responsible banking business model."
All six projects will sell energy to subscribers at fixed prices for an initial 20-year term under the Oregon Community Solar Program. The program requires that at least 10% of the subscriber base be made up of low to moderate income households.

Contracts

AMAL

Amalgamated Financial Corp. Announces Completion Of 3 Oregon Community Solar Program Projects; 3 Additional Projects Are Expected To Be Completed And Commence Operations By The End Of Q3 2024

WIIM

Medifast shares are trading lower after the company reported mixed Q1 financial results.

Offerings

RSVR

Reservoir Media Files For Mixed Shelf Of Up To $100M

LOGCAP is an indefinite delivery indefinite quantity contract with combatant command (COCOM) based task orders. The option period 4 performance is&nbsp;March 2024&nbsp;to&nbsp;March 2025.
Under the terms of the contract,&nbsp;KBR will continue to provide life support, equipment readiness, training and supply chain solutions to the U.S. Army. Currently, KBR supports approximately 20,000 U.S. government personnel across roughly 50 locations in&nbsp;Europe&nbsp;and&nbsp;North America.

KBR Secures $771M In LOGCAP Contract Options To Offer Logistics And Life Support Services To US Army EUCOM And NORTHCOM

Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) ("Heritage" or the "Company"), a super-regional property and casualty insurance holding company announced today that it fully placed its 2024-2025 indemnity based, catastrophe excess-of-loss reinsurance program for its insurance subsidiaries, Heritage Property Casualty Insurance Company, Narragansett Bay Insurance Company, and Zephyr Insurance Company.
"We are delighted to announce the successful completion of our 2024-2025 catastrophe excess of loss reinsurance program," stated Heritage CEO Ernie Garateix. "We value the unwavering support of our valued long-term reinsurance partners as well as new reinsurance partners and reaffirm our commitment to provide appropriate coverage for the markets we serve. I'm pleased to continue to place a portion of our program through capital markets using catastrophe bonds issued by Citrus Re, which provides multi-year reinsurance coverage."
Key points of the 2024-2025 catastrophe reinsurance program include:
<ul>
<li>Total consolidated cost of approximately&nbsp;$422.3 million.</li>
<li>The prior year program included over $70.0 million of limit provided through the Florida Reinsurance to Assist Policyholders ("RAP") program at no cost to the Company. The current year program cost includes replacement of that program with external reinsurance partners.</li>
<li>External party first event reinsurance tower exhaustion points of $1.1 billion for the Northeast, $1.3 billion in the Southeast and $750.0 million in Hawaii. Each reinsurance tower may be supplemented with limit purchased through affiliate Osprey Re.</li>
<li>The 2024 catastrophe excess of loss reinsurance program includes a Southeast-only limit of $100.0 million through catastrophe bonds issued by Citrus Re Ltd., a Bermuda-domiciled special purpose vehicle. This addition complements the existing Citrus Re 2023 catastrophe bonds, which featured a $120.0 million Northeast only limit and a $115.0 million combined Northeast/Hawaii limit, both of which remain unused. Furthermore, the $100 million limit of the 2022 in-force Northeast-only catastrophe bond also remains unutilized and available for the 2024 hurricane season.</li>
<li>The loss retention for the Company is approximately $40.0 million for the Southeast and Hawaii, respectively, and $32 million for the Northeast. The retention for each insurance company could be reduced by limit purchased through affiliate Osprey Re.</li>
<li>Florida Hurricane Catastrophe Fund participation of 90.0%, consistent with the prior year program.</li>
<li>The entire program is indemnity based, with no parametric covers.</li>
</ul>

HRTG

Heritage Announces Full Placement Of 2024-2025 CAT XOL Reinsurance Program; Total Consolidated Cost Of ~$422.3M

BLND

Blend Labs shares are trading higher after the company announced a strategic partnership with Haveli Investments, including a $150 million investment.

Norfolk Southern CEO Alan Shaw Says Disagree With Glass Lewis Siding With Activist Ancora

Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) announced Monday that CEO Bob Bakish is stepping down from the studio&#8217;s as the company continues <a href="https://www.benzinga.com/m-a/24/04/38458769/paramount-skydance-merger-talks-heat-up">merger talks with Skydance Media</a>.
Paramount said George Cheeks (CBS CEO), Chris McCarthy (CEO Showtime/MTV Entertainment Studios and Paramount Media Networks) and Brian Robbins (CEO Paramount Pictures and Nickelodeon) will lead the company moving forward.
"Paramount Global includes exceptional assets and we believe strongly in the future value creation potential of the company. I have tremendous confidence in George, Chris and Brian. They have both the ability to develop and execute on a new strategic plan and to work together as true partners," Paramount Chair Shari Redstone said.
What Happened: Paramount Global reported first-quarter revenue Monday of $7.685 billion, which was up 6% year-over-year. The revenue total missed a Street consensus estimate of $7.732 billion, according to <a href="https://www.benzinga.com/pro/feature/newsfeed?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348">data from Benzinga Pro.</a>
The company reported earnings per share of 62 cents, which beat a Street estimate of 36 cents.
The first-quarter financial results from Paramount come as the company continues merger talks with David Ellison&#8216;s Skydance Media.
Paramount and Skydance have until May 3 to continue exclusive talks on a merger. The period could be extended or Paramount could look to other interested parties after this time.
On Monday, shares of Paramount jumped ahead of earnings with new concessions proposed to Paramount shareholders by Ellison and the Shari Redstone family, which holds a controlling interest in Paramount.
Revenue by segment:
TV Media: $5.23 billion, +1% year-over-year
DTC: $1.88 billion, +24% year-over-year
Filmed Entertainment $601 million, +3% year-over-year
The company's DTC segment saw revenue of streaming platform Paramount+ up 51% year-over-year. Paramount+ added 3.7 million net paid subscribers in the quarter to hit a global total of 71 million paid subscribers.
Advertising revenue for the DTC segment was up 31% year-over-year. The average revenue per user for Paramount+ was up 26% year-over-year.
The company's TV segment was boosted by Super Bowl LVIII in the quarter, which helped boost advertising revenue by 14% year-over-year. The company said the Super Bowl contributed a 23-point benefit to advertising.
Total advertising revenue across segments was up 17% year-over-year.
"The team delivered another quarter of strong operational and financial performance – including significant growth in total company earnings and free cash flow – despite the dynamic environment we continue to operate in," Paramount Chief Financial Officer Naveen Chopra said.
Chopra said Paramount+ saw record engagement and revenue in the quarter.
Related Link: <a href="https://www.benzinga.com/news/24/04/38092842/expert-says-paramount-global-reportedly-snubbing-26b-offer-from-apollo-global-doesnt-make-sense">Analyst Says Paramount Global Reportedly Snubbing $26B Offer From Apollo Global &#8216;Doesn&#8217;t Make Sense&#8217;</a>
PARA Price Action: Paramount shares gained 2.85% in Monday&#8217;s regular trading session to close at $12.25 versus a 52-week trading range of $10.12 to $24.
Read Next: <a href="https://www.benzinga.com/general/entertainment/24/04/38148539/paramount-skydance-deal-could-be-home-run-for-shari-redstone-loss-for-shareholders-investor">Paramount, Skydance Deal Could Be &#8216;Home Run&#8217; For Shari Redstone, Loss For Shareholders, Investor Warns</a>
Photo via Shutterstock.

Entertainment

Equities

PARA

PARAA

Paramount CEO Bob Bakish Out As Skydance Merger Talks Continue: Studio Misses Q1 Revenue Estimates, Beats On Earnings

<h3>Gainers</h3>
<ul>
<li>LL Flooring Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) shares rose 25.8% to $1.95 during Monday's after-market session. The company's market cap stands at $55.8 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares increased by 8.3% to $3.0. The company's market cap stands at $9.3 million. </li>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) stock increased by 4.66% to $0.17. The market value of their outstanding shares is at $8.8 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares rose 3.29% to $0.28. The market value of their outstanding shares is at $14.7 million. </li>
<li>Qurate Retail (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEA#NASDAQ">QRTEA</a>) shares moved upwards by 2.59% to $0.91. The company's market cap stands at $356.4 million. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock increased by 2.21% to $2.77. The company's market cap stands at $296.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) stock declined by 16.7% to $9.9 during Monday's after-market session. The company's market cap stands at $1.5 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 8.19% to $0.48. The company's market cap stands at $3.2 million. </li>
<li>J-Long Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) stock declined by 5.0% to $0.76. The company's market cap stands at $23.8 million. </li>
<li>Golden Sun Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSUN#NASDAQ">GSUN</a>) stock fell 4.59% to $2.5. The market value of their outstanding shares is at $4.7 million. </li>
<li>Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares decreased by 4.47% to $6.85. The market value of their outstanding shares is at $695.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Cenntro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENN#NASDAQ">CENN</a>) stock declined by 3.9% to $1.48. The company's market cap stands at $45.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CENN

CHGG

COUR

GDHG

GSUN

LXEH

NRDY

QRTEA

ZAPP

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) reported quarterly earnings of $0.66 per share which missed the analyst consensus estimate of $0.78 by 15.38 percent. This is a 82.02 percent decrease over earnings of $3.67 per share from the same period last year. The company reported quarterly sales of $174.739 million which beat the analyst consensus estimate of $168.900 million by 3.46 percent. This is a 49.93 percent decrease over sales of $348.983 million the same period last year.

Medifast Q1 2024 Adj EPS $0.66 Misses $0.78 Estimate, Sales $174.739M Beat $168.900M Estimate

<h3>Gainers</h3>
<ul>
<li>GeneDx Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings came out today. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares increased by 7.25% to $3.99. The market value of their outstanding shares is at $542.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares increased by 5.48% to $0.25. The market value of their outstanding shares is at $2.5 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock moved upwards by 5.23% to $0.79. The market value of their outstanding shares is at $38.1 million. </li>
<li>Seelos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) shares increased by 4.88% to $0.29. The market value of their outstanding shares is at $4.0 million. </li>
<li>NewAmsterdam Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) shares increased by 4.8% to $22.7. The market value of their outstanding shares is at $2.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock declined by 10.7% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $13.3 million. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) stock decreased by 9.44% to $0.14. The company's market cap stands at $18.1 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 5.43% to $1.22. The market value of their outstanding shares is at $21.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) shares declined by 5.0% to $0.67. The company's market cap stands at $11.3 million. </li>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock decreased by 4.98% to $4.2. The market value of their outstanding shares is at $259.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares fell 4.73% to $4.24. The market value of their outstanding shares is at $51.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COSM

EKSO

GCTK

INNV

INZY

LUCD

MBIO

NAMS

SEEL

VAXX

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Jet AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares increased by 9.7% to $0.79 during Monday's after-market session. The market value of their outstanding shares is at $9.6 million. </li>
<li>Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) shares moved upwards by 6.41% to $160.76. The company's market cap stands at $9.6 billion. The company's, Q2 earnings came out today. </li>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) stock rose 5.18% to $0.74. The market value of their outstanding shares is at $11.1 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares increased by 4.2% to $2.76. The company's market cap stands at $223.8 million. </li>
<li>SolarMax Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) stock moved upwards by 3.85% to $11.59. The company's market cap stands at $524.4 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock increased by 3.16% to $0.62. The market value of their outstanding shares is at $10.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares declined by 5.7% to $0.7 during Monday's after-market session. The company's market cap stands at $12.7 million. </li>
<li>Lichen China (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) shares declined by 5.42% to $1.92. The company's market cap stands at $52.5 million. </li>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares decreased by 4.99% to $0.47. The company's market cap stands at $6.3 million. </li>
<li>GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares decreased by 4.66% to $14.33. The company's market cap stands at $1.8 billion. </li>
<li>Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) shares fell 3.88% to $0.7. The company's market cap stands at $34.4 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares decreased by 3.21% to $1.21. The company's market cap stands at $46.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

CSLR

ELWS

ILAG

JTAI

LGCL

LICN

MNTS

SMXT

VCIG

12 Industrials Stocks Moving In Monday's After-Market Session

Ability to dose TERN-701 without regard to food represents a key potential differentiator within the&nbsp;allosteric BCR-ABL inhibitor class
Pharmacokinetic data show no clinically significant difference in exposure between fed and fasted dosing
Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of 2024
FOSTER CITY, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced findings from a Phase 1 study of TERN-701 in Western healthy volunteers. The study is an ongoing Phase 1 open-label, single ascending dose trial to evaluate the pharmacokinetics (PK), food effect, safety and tolerability of TERN-701 in healthy adults. TERN-701 is Terns' proprietary, oral, potent, allosteric BCR-ABL inhibitor, a novel class of therapy for CML that has demonstrated superior efficacy and safety compared to traditional active-site tyrosine kinase inhibitors (TKIs).
"We are pleased with the interim findings from this healthy volunteer study, which indicate TERN-701 can be administered once-daily (QD) with or without food at doses that achieve clinically efficacious exposures. TERN-701 has the potential to be a differentiated BCR-ABL inhibitor with advantages over asciminib, including more convenient dosing to improve treatment options and quality of life for people living with CML," said Emil Kuriakose, MD, chief medical officer at Terns Pharmaceuticals.&nbsp;&nbsp;
"We are excited to see clinical PK data continuing to support once-daily dosing and new data showing lack of food effect with TERN-701. The ability to dose with or without food is a key potential differentiator from asciminib, the only currently approved allosteric BCR-ABL inhibitor, which requires three hours of fasting with each dose, and twice-daily dosing in multiple clinical settings. We look forward to reporting interim dose escalation data from the ongoing Phase 1 CARDINAL trial in the second half of 2024," concluded Dr. Kuriakose.
The Phase 1 single-ascending dose (SAD) trial is ongoing in the United States and has enrolled 32 healthy volunteers in four dose escalation cohorts of eight participants each to evaluate PK, food effect and safety and tolerability at single doses ranging from 20 mg to 160 mg. No clinically meaningful changes or trends were observed in clinical laboratory data, vital signs or electrocardiogram (ECG) parameters at any dose level. Across the dose range administered to date, TERN-701 PK was linear with a median half-life ranging from 8 to 12 hours. At the 80 mg and 160 mg doses, TERN-701 exposures over 24 hours met or exceeded the predicted efficacious concentrations based on preclinical data1, consistent with observed clinical activity and safety at these doses in the ongoing Phase 1 study in China conducted by our partner, Hansoh Pharmaceuticals. Overall, the PK profile of TERN-701 in Western participants was generally consistent with that observed in the Phase 1 clinical study in Chinese CML patients.
Results of the food effect evaluation at 80 mg of TERN-701 showed no clinically significant differences in plasma exposures (area under curve, AUC) when dosed with a high-fat meal, relative to the fasted state. These results support potential dosing of TERN-701 with or without food, an initial differentiation for TERN-701 as a potentially best-in-class allosteric BCR-ABL inhibitor.
The Phase 1 healthy volunteer study remains ongoing and will proceed to enroll 320 mg and 400 mg dose cohorts. Terns plans to present these healthy volunteer data at an upcoming scientific conference.
Phase 1 CARDINAL Trial Design The CARDINAL trial is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, PK, and efficacy of TERN-701 in participants with previously treated CML. Part 1 is the dose escalation portion of the trial that will evaluate once-daily TERN-701 monotherapy in approximately 24-36 adults living with CML to be enrolled in up to five dose cohorts. Participants will have chronic phase CML with confirmed BCR-ABL and a history of treatment failure or suboptimal response to at least one second generation TKI (nilotinib, dasatinib or bosutinib). Participants who are intolerant to prior TKI treatment (including asciminib) are also allowed. The primary endpoints for Part 1 are the incidence of dose limiting toxicities (DLTs) during the first treatment cycle, and additional measures of safety and tolerability. Secondary endpoints include TERN-701 PK and efficacy assessments, such as hematologic and molecular responses as measured by the change from baseline in BCR-ABL transcript levels. The starting dose is 160 mg QD with dose escalations as high as 500 mg QD and the option to explore a lower dose of 80 mg QD.
Part 2 is the dose expansion portion of the trial that is planned to enroll approximately 40 patients, randomized to QD treatment with one of two doses of TERN-701 to be selected based on data from Part 1. The primary endpoint of the dose expansion portion of the trial is efficacy, measured by hematologic and molecular responses. Secondary endpoints include safety, tolerability and PK. The overall objective of the CARDINAL trial is to select the optimal dose(s) of TERN-701 to move forward to a potential pivotal trial in chronic phase CML.
The CARDINAL trial plans to enroll at sites in the U.S., Europe and other Terns global territories.
About TERN-701 TERN-701 is Terns' proprietary, oral, potent, allosteric BCR-ABL inhibitor specifically targeting the BCR-ABL myristoyl pocket and is in clinical development for chronic myeloid leukemia. Allosteric inhibitors, which bind to the myristoyl-binding pocket, represent a novel treatment class for CML and have the potential to address the shortcomings of active-site TKIs, including off-target activity and limited efficacy against active site resistance mutations. TERN-701 aims to address the limitations of active-site TKIs with the goal of achieving improved tumor suppression through a combination of potent activity against BCR-ABL including a broad range of mutations and improved safety and tolerability profiles. Hansoh's Phase 1 trial (NCT05367700) evaluating the tolerability, efficacy, and pharmacokinetics of once-daily TERN-701 (HS-10382) for CML in China is ongoing.

Biotech

General

TERN

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study Of Allosteric BCR-ABL Inhibitor TERN-701 In Adult Healthy Volunteers And Highlights Potential For Competitive Differentiation

<h3>Gainers</h3>
<ul>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares rose 37.9% to $3.6 during Monday's after-market session. The market value of their outstanding shares is at $10.8 million. </li>
<li>Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) shares rose 21.77% to $2.74. The market value of their outstanding shares is at $690.6 million. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares rose 7.14% to $0.31. The market value of their outstanding shares is at $20.2 million. </li>
<li>Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares rose 7.11% to $33.71. The market value of their outstanding shares is at $8.2 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Inseego (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) stock moved upwards by 5.26% to $4.4. The market value of their outstanding shares is at $52.2 million. </li>
<li>ClearOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>) stock rose 4.99% to $0.95. The company's market cap stands at $22.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) shares declined by 11.1% to $162.0 during Monday's after-market session. The company's market cap stands at $9.5 billion. The company's, Q2 earnings came out today. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares declined by 6.25% to $60.0. The market value of their outstanding shares is at $3.3 billion. The company's, Q2 earnings came out today. </li>
<li>OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) stock decreased by 6.0% to $0.4. The company's market cap stands at $4.2 million. </li>
<li>Hitek Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HKIT#NASDAQ">HKIT</a>) shares declined by 5.97% to $1.42. The company's market cap stands at $20.4 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock decreased by 4.84% to $2.36. The company's market cap stands at $22.6 million. </li>
<li>Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 4.36% to $73.51. The company's market cap stands at $10.1 billion. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

CLRO

FCUV

FFIV

HKIT

INSG

LSCC

MRIN

OMQS

SMSI

12 Information Technology Stocks Moving In Monday's After-Market Session

Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.65 by 9.23 percent. The company reported quarterly sales of $2.96 billion which missed the analyst consensus estimate of $3.05 billion by 2.90 percent. This is a 1.47 percent increase over sales of $2.92 billion the same period last year.

YUMC

Yum China Holdings Q1 2024 Adj EPS $0.71 Beats $0.65 Estimate, Sales $2.96B Miss $3.05B Estimate

Financial giants have made a conspicuous bearish move on Wingstop. Our analysis of options history for Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $142,935, and 4 were calls, valued at $266,142.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $280.0 to $460.0 for Wingstop over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Wingstop stands at 127.12, with a total volume reaching 188.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Wingstop, situated within the strike price corridor from $280.0 to $460.0, throughout the last 30 days.
<h3>Wingstop Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714422657_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$107.4</td>
<td>$106.0</td>
<td>$106.0</td>
<td>$280.00</td>
<td>$159.0K</td>
<td style="text-align: right;">113</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$23.1</td>
<td>$22.8</td>
<td>$23.1</td>
<td>$390.00</td>
<td>$57.7K</td>
<td style="text-align: right;">26</td>
<td style="text-align: right;">26</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$24.5</td>
<td>$24.0</td>
<td>$24.0</td>
<td>$380.00</td>
<td>$48.0K</td>
<td style="text-align: right;">307</td>
<td style="text-align: right;">32</td>
</tr>
<tr>
<td>WING</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$98.8</td>
<td>$96.5</td>
<td>$98.8</td>
<td>$290.00</td>
<td>$29.6K</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>WING</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$39.0</td>
<td>$37.0</td>
<td>$37.0</td>
<td>$400.00</td>
<td>$29.6K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">8</td>
</tr>
</tbody>
</table>

<h3>About Wingstop</h3>
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, reaching north of 2,200 global stores at the end of 2023, rendering Wingstop the 31st-largest restaurant brand in the U.S. by system sales, according to Euromonitor data. With a 98% franchised model, Wingstop generates the lion share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
After a thorough review of the options trading surrounding Wingstop, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Wingstop</h3>
<ul>
<li>With a volume of 715,464, the price of WING is up 0.59% at $384.82. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What Analysts Are Saying About Wingstop</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $346.8.
<ul>
<li>An analyst from Truist Securities persists with their Hold rating on Wingstop, maintaining a target price of $307. </li>
<li>Reflecting concerns, an analyst from TD Cowen lowers its rating to Buy with a new price target of $410.</li>
<li>Reflecting concerns, an analyst from TD Cowen lowers its rating to Buy with a new price target of $410.</li>
<li>Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Wingstop, targeting a price of $315. </li>
<li>An analyst from Truist Securities persists with their Hold rating on Wingstop, maintaining a target price of $292. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wingstop options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

WING

Spotlight on Wingstop: Analyzing the Surge in Options Activity

Flowserve Raises FY24 Adj. EPS From $2.40-$2.60 To $2.50-$2.70 Vs $2.54 Est.

Brad Simpson On Rising Iran-Israel Tensions And The Implications For Markets

Investors in the US have become jaded. There are many versions of how to illustrate that, but the one focused on here is the belief that the US stock market is a perennial performance juggernaut. The world stock markets have a lot to offer.

Global ETFs: Why Going Outside Our Borders Could Pay Off Handsomely

Equity Investing Is About The Way Things Are, Not The Way Things Should Be

S&P 500 Earnings: So Far, The Pattern Is Typical, But Mega-Cap Earnings This Week Loom Large

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Invesco Russell 1000 Equal Weight ETF (ARCA:EQAL)

Monday, November 09, 2015

Friday, October 09, 2015

Tuesday, September 29, 2015